Mepivacaine B. Braun (Mepivacaine Hydrochloride)

Mepivacaine works by reversibly blocking voltage‑gated sodium channels on nerve membranes. This inhibition prevents the initiation and conduction of action potentials, thereby stopping the transmission of pain signals from the site of injection to the central nervous system.

The specific dose of Mepivacaine B. Braun is determined by the prescribing clinician based on the type of procedure, patient weight, age, and clinical condition. Only a qualified health professional should calculate and administer the appropriate volume.

Mepivacaine is classified as pregnancy category unknown. It should be used during pregnancy or lactation only when the potential therapeutic benefit justifies any possible risk to the fetus or infant, and after a careful risk‑benefit assessment by the treating physician.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Mepivacaine is often compared with lidocaine, another amide‑type local anesthetic. Both have rapid onset, but mepivacaine typically provides a slightly longer duration of action and is less vasodilatory, which can reduce the need for a vasoconstrictor in certain procedures.

Store the solution at or below 25 °C in its original packaging, protecting it from direct sunlight, moisture and extreme temperatures. Do not freeze the product. Inspect the vial for particulate matter or discoloration before use.

Mepivacaine B. Braun is administered by a qualified health professional via epidural, intramuscular or perineural injection. The injection technique follows standard aseptic procedures, and the dose is adjusted to the specific clinical situation and patient characteristics.

Serious risks include severe allergic reactions (anaphylaxis), cardiac toxicity such as arrhythmias or cardiac arrest, and central nervous system toxicity that can manifest as seizures or loss of consciousness. Immediate medical intervention is required if any of these events occur.

Patients with a known hypersensitivity to mepivacaine or other amide‑type local anesthetics should avoid its use. It is also contraindicated in individuals with severe cardiac conduction disorders, uncontrolled epilepsy, or those who have experienced previous severe systemic toxicity from local anesthetics.